KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Debt (2018 - 2021)

TherapeuticsMD (TXMD) has disclosed Non-Current Debt for 5 consecutive years, with $171.7 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Non-Current Debt fell 27.55% year-over-year to $171.7 million, compared with a TTM value of $171.7 million through Sep 2021, down 27.55%, and an annual FY2020 reading of $237.7 million, up 22.13% over the prior year.
  • Non-Current Debt was $171.7 million for Q3 2021 at TherapeuticsMD, down from $175.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $243.8 million in Q2 2020 and bottomed at $73.1 million in Q2 2018.
  • Average Non-Current Debt over 4 years is $168.9 million, with a median of $186.5 million recorded in 2019.
  • The sharpest move saw Non-Current Debt surged 231.19% in 2020, then fell 28.11% in 2021.
  • Year by year, Non-Current Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then fell by 27.75% to $171.7 million in 2021.
  • Business Quant data shows Non-Current Debt for TXMD at $171.7 million in Q3 2021, $175.3 million in Q2 2021, and $179.0 million in Q1 2021.